Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
MGTA Stock Summary
In the News
10 Best-Performing Penny Stocks in the Health Care Sector
The healthcare sector has more high return generating companies than many other sectors.
Easing Banking Fears, Rate Hike Pause Boost Markets: 5 Picks
Thanks to the easing concerns in the banking sector and the Fed's willingness to pause rate hikes, it's wise to invest in growth stocks like Blue Bird (BLBD), Salesforce (CRM), and Deckers Outdoor (DECK).
MGTA Stock: 51.66% Surge Explained
The stock price of Magenta Therapeutics Inc (NASDAQ: MGTA) surged by 51.66% in the most recent trading session. This is why.
Magenta (MGTA) Down on Pipeline Update for Leukemia Drug
Magenta Therapeutics (MGTA) stops dosing participants in a phase I/II study cohort, evaluating its blood cancer pipeline candidate due to dose-limiting toxicities.
Why The Magenta Therapeutics (MGTA) Stock Plummeted Over 50%
The stock price of Magenta Therapeutics (MGTA) plummeted over 50% intraday today. This is why.
Magenta Therapeutics to Host Conference Call and Webcast on Tuesday, December 13, 2022, to Review MGTA-117 Clinical Data from Ongoing Phase 1/2 Clinical Trial
CAMBRIDGE, Mass., Dec. 12, 2022 (GLOBE NEWSWIRE) -- Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplant to more patients, today announced that it will host a conference call and webcast at 8:30 a.m. Eastern Time (ET) / 7:30 a.m. Central Time (CT) tomorrow, Tuesday, December 13, 2022 to review the MGTA-117 clinical data from its ongoing Phase 1/2 does escalation clinical trial that will be presented at the 2022 American Society of Hematology (ASH) Annual Meeting.
After Plunging 49.1% in 4 Weeks, Here's Why the Trend Might Reverse for Magenta Therapeutics, Inc. (MGTA)
The heavy selling pressure might have exhausted for Magenta Therapeutics, Inc. (MGTA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Magenta Therapeutics Trims R&D, Cuts Workforce
Magenta Therapeutics Inc (NASDAQ: MGTA) is cutting 14% of staff and axing a planned dosing optimization trial for a stem cell mobilization med, focused on extending its cash runway into Q2 2024. The cost-saving measures focus on shaving administrative expenses and new research.
Big Pharma Is Going Holiday Shopping. Who's Next?
After an infusion of cash from COVID-19 treatments, many companies are on the lookout for acquisitions.
Week 38 MDA Breakout Stocks - September 2021: Short-Term Picks To Give You An Edge
Two new Breakout Stocks for Week 38 with better than 10% short-term upside potential. The ETF/ETN forecast section now goes out in a separate article. Following the Momentum Gauges, the portfolio is up +57.6% YTD with a record high of 22 out of 37 weeks this year in negative conditions above the 40 MG level.
MGTA Financial details
MGTA Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -59.42 | -35.28 | -29.93 | -22.67 | -23.05 | |
Operating cash flow per share | -43.28 | -29.31 | -27.7 | -20.58 | -21.47 | |
Free cash flow per share | -51.2 | -30.88 | -27.87 | -21.02 | -21.57 | |
Cash per share | 147.3 | 74.8 | 64.39 | 61.18 | 35.85 | |
Book value per share | 150.48 | 72.48 | 62.25 | 59.71 | 33.91 | |
Tangible book value per share | 150.48 | 72.48 | 62.25 | 59.71 | 33.91 | |
Share holders equity per share | 150.48 | 72.48 | 62.25 | 59.71 | 33.91 | |
Interest debt per share | 0 | 0 | 0 | 0 | 8.17 | |
Market cap | 5.52M | 29.53M | 18.12M | 12.81M | 1.23M | |
Enterprise value | -52.83M | -35.54M | -40.03M | -118.84M | -26.43M | |
P/E ratio | -0.1 | -0.43 | -0.26 | -0.2 | -0.02 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | -0.13 | -0.52 | -0.28 | -0.22 | -0.02 | |
PFCF ratio | -0.11 | -0.49 | -0.28 | -0.21 | -0.02 | |
P/B Ratio | 0.04 | 0.21 | 0.13 | 0.07 | 0.01 | |
PTB ratio | 0.04 | 0.21 | 0.13 | 0.07 | 0.01 | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | 0.88 | 0.43 | 0.51 | 1.59 | 0.33 | |
EV to operating cash flow | 1.26 | 0.62 | 0.63 | 2 | 0.39 | |
EV to free cash flow | 1.07 | 0.59 | 0.62 | 1.95 | 0.39 | |
Earnings yield | -10.43 | -2.33 | -3.82 | -5.12 | -58.35 | |
Free cash flow yield | -8.98 | -2.04 | -3.55 | -4.75 | -54.61 | |
Debt to equity | 0 | 0 | 0 | 0 | 0.28 | |
Debt to assets | 0 | 0 | 0 | 0 | 0.2 | |
Net debt to EBITDA | 0.97 | 0.78 | 0.74 | 1.76 | 0.35 | |
Current ratio | 13.95 | 10.62 | 13.26 | 16.29 | 7.95 | |
Interest coverage | 0 | 0 | 0 | 0 | 18.22 | |
Income quality | 0.73 | 0.74 | 0.85 | 0.84 | 0.88 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0.18 | 0.05 | 0.01 | 0.02 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | -8.77 | -1.66 | -0.2 | -0.63 | -0.16 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 448.56 | 239.85 | 204.76 | 174.51 | 132.61 | |
ROIC | -0.43 | -0.53 | -0.5 | -0.4 | -0.46 | |
Return on tangible assets | -0.37 | -0.43 | -0.43 | -0.35 | -0.49 | |
Graham Net | 135.25 | 64.37 | 56.72 | 55.21 | 22.83 | |
Working capital | 134.9M | 135.73M | 140.1M | 166.06M | 101.05M | |
Tangible asset value | 145.65M | 141.19M | 143.91M | 172.67M | 105.96M | |
Net current asset value | 133.66M | 129.52M | 133.81M | 159.66M | 74.92M | |
Invested capital | 0 | 0 | 0 | 0 | 0.28 | |
Average receivables | 0 | 0 | 0 | 0 | 0 | |
Average payables | 1.83M | 3.15M | 3.29M | 3.4M | 2.75M | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0 | 0 | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -0.39 | -0.49 | -0.48 | -0.38 | -0.68 | |
Capex per share | -7.93 | -1.57 | -0.17 | -0.44 | -0.1 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -5.53 | -7.38 | -8.21 | -1.03 | -3.78 | |
Operating cash flow per share | -4.43 | -5.34 | -11.15 | -2.05 | 0 | |
Free cash flow per share | -4.48 | -5.39 | -11.23 | -2.05 | 0 | |
Cash per share | 41.12 | 35.85 | 24.5 | 24.31 | 48.6 | |
Book value per share | 39.76 | 33.91 | 24.27 | 23.37 | 45.66 | |
Tangible book value per share | 39.76 | 33.91 | 24.27 | 23.37 | 45.66 | |
Share holders equity per share | 39.76 | 33.91 | 24.27 | 23.37 | 45.66 | |
Interest debt per share | 10.25 | 8.66 | -0.93 | 0 | 0.17 | |
Market cap | 4.4M | 1.23M | 2.54M | 2.42M | 2.73M | |
Enterprise value | -23.83M | -26.43M | -45.99M | -60.21M | -153.88M | |
P/E ratio | -0.06 | -0.01 | -0.02 | -0.18 | -0.05 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | -0.32 | -0.07 | -0.07 | -0.37 | 0 | |
PFCF ratio | -0.31 | -0.07 | -0.07 | -0.37 | 0 | |
P/B Ratio | 0.04 | 0.01 | 0.03 | 0.03 | 0.02 | |
PTB ratio | 0.04 | 0.01 | 0.03 | 0.03 | 0.02 | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | 1.42 | 1.24 | -10.7 | 17.01 | 9.76 | |
EV to operating cash flow | 1.73 | 1.58 | 1.29 | 9.2 | 0 | |
EV to free cash flow | 1.71 | 1.57 | 1.28 | 9.2 | 0 | |
Earnings yield | -3.92 | -18.69 | -10.33 | -1.36 | -5.4 | |
Free cash flow yield | -3.18 | -13.65 | -14.13 | -2.7 | 0 | |
Debt to equity | 0.25 | 0.28 | 0 | 0 | 0 | |
Debt to assets | 0.19 | 0.2 | 0 | 0 | 0 | |
Net debt to EBITDA | 1.68 | 1.3 | -11.29 | 17.7 | 9.94 | |
Current ratio | 10.22 | 7.95 | 13.95 | 19.49 | 14.64 | |
Interest coverage | -14.5 | 7.53 | -1.31 | 0 | 0 | |
Income quality | 0.86 | 0.83 | 1.22 | 1.99 | 0 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0.01 | 0.01 | 0.01 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | -0.34 | -0.33 | -0.58 | 0 | 0 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 70.34 | 75.04 | 66.96 | 23.26 | 62.3 | |
ROIC | -0.1 | -0.15 | 0.04 | 0.08 | -0.09 | |
Return on tangible assets | -0.11 | -0.16 | -0.31 | -0.04 | -0.08 | |
Graham Net | 28.27 | 22.83 | 22.63 | 23.04 | 45.09 | |
Working capital | 119.18M | 101.05M | 77.46M | 74.6M | 178.37M | |
Tangible asset value | 124.03M | 105.96M | 77.46M | 74.6M | 178.38M | |
Net current asset value | 92M | 74.92M | 77.46M | 74.6M | 177.37M | |
Invested capital | 0.25 | 0.28 | 0 | 0 | 0 | |
Average receivables | 0 | 0 | 0 | 0 | 259.5K | |
Average payables | 2.31M | 2.52M | 1.77M | 946.5K | 1.09M | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0 | 0 | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -0.14 | -0.22 | -0.34 | -0.04 | -0.08 | |
Capex per share | -0.05 | -0.05 | -0.08 | 0 | 0 |
MGTA Frequently Asked Questions
What is Magenta Therapeutics, Inc. stock symbol ?
Magenta Therapeutics, Inc. is a US stock , located in Cambridge of Ma and trading under the symbol MGTA
What is Magenta Therapeutics, Inc. stock quote today ?
Magenta Therapeutics, Inc. stock price is $- today.
Is Magenta Therapeutics, Inc. stock public?
Yes, Magenta Therapeutics, Inc. is a publicly traded company.